QGENHealthcare · Diagnostics & ResearchThe 15 Wall Street analysts covering Qiagen NV hold a median 12-month price target of $47 — +9.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 8 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Qiagen NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Momentum (38): The shares have been drifting down relative to others.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on QGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Citigroup | Maintains | Neutral | $38 → $45 |
| 7 Aug 2026 | Barclays | Maintains | Equal-Weight | $38 → $40 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $45 → $50 |
| 23 June 2026 | Morgan Stanley | Upgrade | Overweight | $40 → $42 |
| 23 June 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 18 May 2026 | Stifel | Maintains | Hold | — |
| 7 May 2026 | TD Cowen | Maintains | Hold | — |
| 29 Apr 2026 | Baird | Upgrade | Outperform | — |
| 29 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 29 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 29 Apr 2026 | JP Morgan | Maintains | Overweight | — |
| 14 Apr 2026 | Barclays | Downgrade | Equal-Weight | — |
| 13 Mar 2026 | Deutsche Bank | Upgrade | Buy | — |
| 6 Feb 2026 | Citigroup | Maintains | Neutral | — |
| 6 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 6 Feb 2026 | Stifel | Maintains | Hold | — |
| 22 Jan 2026 | Deutsche Bank | Downgrade | Hold | — |
| 15 Dec 2025 | Barclays | Maintains | Overweight | — |
| 11 Dec 2025 | Citigroup | Downgrade | Neutral | — |
| 2 Oct 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QGEN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Sept 2026, Qiagen NV returned −8.8% against +18.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 36% of US stocks
Cheaper than 30% of US stocks
Cheaper than 38% of US stocks
Cheaper than 27% of US stocks
Higher than 28% of US stocks
Higher than 44% of US stocks
Higher than 77% of US stocks
Higher than 85% of US stocks
Higher than 82% of US stocks
Higher than 68% of US stocks
Higher than 81% of US stocks
Higher than 17% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Qiagen NV has a market value of $8.8B and an enterprise value of $9.8B.
Revenue in the twelve months to 30 June 2026: $2.1B. The latest quarter grew 0.3% year on year.
Net income over the same four quarters: $409.3M, a 19.5% net margin.
Diluted earnings per share, trailing twelve months: $1.98.
Free cash flow in the twelve months to 30 June 2026: $440.6M.
Trailing P/E: 21.5×; forward P/E: 16.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.81%, paying out 18% of earnings.
Qiagen NV employs 5,500 people — $382K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Qiagen NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Qiagen (QGEN) reported earnings approximately 30 days ago and its share price has risen 5.1% since that report. Zacks Investment Research examines whether the stock can continue this upward movement.
Why it matters — A QGEN watcher would care because the analysis addresses whether the post-earnings price gain is sustainable going forward.
A U.S. District Court jury in Delaware found that Parse Biosciences, now a Qiagen subsidiary, willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics. The jury also rejected Parse's invalidity challenge.
Why it matters — Qiagen shareholders may face financial and legal consequences from the willful infringement verdict involving its newly acquired Parse Biosciences subsidiary.
QIAGEN announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. The platform builds on the QIAsymphony system, which has more than 3,300 cumulative placements worldwide, and helps clinical laboratories standardize extraction across diverse assay workflows.
Why it matters — This launch expands QIAGEN's automated clinical extraction product line, potentially strengthening its position in the clinical laboratory market.
QIAGEN N.V. announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. Pratt brings more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare, having most recently served as President and CEO of Filtration Group.
Why it matters — A QGEN watcher would care because this appointment sets the company's senior leadership direction, bringing an experienced life-sciences and healthcare executive to guide the business.
QIAGEN announced that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. This clearance expands QIAGEN's U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform.
Why it matters — The FDA clearance adds a new infectious disease category to QIAGEN's U.S. QIAstat-Dx syndromic testing portfolio, broadening the platform's diagnostic market reach.
The 15 Wall Street analysts covering Qiagen NV have a median 12-month price target of $47, with estimates ranging from $40 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Qiagen NV, 8 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Qiagen NV 63 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Sept 2026, Qiagen NV ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +9.4% from the last close, and Ticker Nerd's factor model ranks Qiagen NV 63 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Qiagen NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $50 over the next 12 months.
Qiagen NV returned -8.8% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research.
The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?". Qiagen (QGEN) reported earnings approximately 30 days ago and its share price has risen 5.1% since that report. Zacks Investment Research examines whether the stock can continue this upward movement.
Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials. Its portfolio supports workflows in areas such as genotyping, gene expression, viral and bacterial analysis, next-generation sequencing, forensic testing, and clinical decision support. The company serves laboratories, healthcare organizations, research institutions, and life science companies worldwide, making it a key supplier in molecular testing and research workflows. Qiagen N.V. is headquartered in Venlo, the Netherlands, with major operational activities in Hilden, Germany.
CEO Mr. Thierry L. Bernard · 5,500 employees · Netherlands · https://www.qiagen.com
